Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Summary The epigenome is a key determinant of transcriptional output. Perturbations within the epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear that epigenetic changes are instrumental in cancer development. The inherent reversibility of these changes makes them attractive targets for therapeutic manipulation and a number of small molecules targeting chromatin-based mechanisms are currently in clinical trials. In this perspective we discuss how understanding the cancer epigenome is providing insights into disease pathogenesis and informing drug development. We also highlight additional opportunities to further unlock the therapeutic potential within the cancer epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“Rewiring of signaling programs and epigenomic changes are increasingly being recognized as mechanisms of acquired drug resistance (Brown et al., 2014; Holohan et al., 2013; Sharma et al., 2010).”
BackgroundSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“Moreover, pre-clinical studies have indicated that combination therapies involving HDAC inhibitors and some of the emerging epigenetic therapies may prove clinically beneficial (Fiskus et al., 2014; Mazur et al., 2015).”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“Localized hypermethylation of gene-promoter regions leading to transcriptional repression of tumor-suppressor genes such as CDKN2A and RB1 were subsequently found to be a common feature of many cancers (Baylin and Jones, 2011).”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
The NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 5×
“focused genomic screening techniques, particularly those utilizing the CRISPR/Cas9-mediated genome-editing technology, are already facilitating the identification of epigenetic dependencies in cancer cells (Shi et al., 2015; Zuber et al., 2011).”
BackgroundMethodInfluentialEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 12×
“Based on these preclinical successes, some of these compounds have now entered phase I clinical trials for the treatment of relapsed refractory B cell lymphoma and advanced solid tumors (Figure 2, and discussed further below), namely, NCT02395601, NCT01897571, and NCT02082977 at https://clinicaltrials.gov.”
BackgroundInfluentialPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · cited 1×
“Moreover, novel approaches to drug design such as the use of phthalimide conjugates to mediate proteosomal degradation of target proteins may overcome several limitations of conventional small molecules (Winter et al., 2015).”
BackgroundFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · cited 1×
“The histone methyltransferase (HMT) EZH2 is subject to recurrent gain-of-function mutations in B cell lymphoma (Morin et al., 2010, 2011).”
BackgroundThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 3×
“…(suberoylanilide hydroxamic acid [SAHA]), which inhibits the activity of histone deacetylase (HDAC) enzymes, leading to global increases in histone acetylation, was granted FDA approval for the treatment of advanced cutaneous T cell lymphoma in 2006 (Mann et al., 2007; Wagner et al., 2010).”
BackgroundInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 1×
“…tumors (MPNSTs), melanomas, and glioblastomas leads to global increases in H3K27 acetylation (H3K27ac) and H3K36me1/2/3 (De Raedt et al., 2014; Ernst et al., 2010; Jaffe et al., 2013; Lee Cancer Cell 29, April 11, 2016 471 et al., 2014; Nikoloski et al., 2010; Ntziachristos et al., 2012;…”
BackgroundHistone core modifications regulating nucleosome structure and dynamics
Tessarz, P., & Kouzarides, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3890 · Cited by 1,018
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“However, resistance often emerges owing to upregulation of alternative receptor tyrosine kinase (RTK) genes, which compensate for the inhibited enzyme (Azuma et al., 2011; Britschgi et al., 2012; Chandarlapaty et al., 2011; Rexer et al., 2011).”
BackgroundAn oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722 · cited 3×
“Selection of Targeted Epigenetic Therapies in Use or under Clinical Investigation in Cancer Patients Protein Biological Function Cancer Type Small-Molecule(s) Clinical Trial References Chromatin Writers DOT1L H3K79 methylation AML, ALL EPZ-5676 NCT01684150, NCT02141828 Daigle et al., 2013 EZH2 H3K27 methylation non-Ho…”
BackgroundSchenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672 · cited 4×
“Significantly, recent studies using both genetic inactivation and pharmacologic inhibition of LSD1 in the context of AML have provided evidence for a functional link between LSD1 and leukemia (Harris et al., 2012; Schenk et al., 2012).”
BackgroundInfluentialResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 1×
“Significantly, a distinct mechanism of BET inhibitor resistance has been described in triple-negative breast cancer cells (Shu et al., 2016).”
BackgroundThe histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545
Hayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · cited 2×
“Since this initial success, the HDAC inhibitors romidepsin and panobinostat have been approved for use in cutaneous T cell lymphoma and multiple myeloma, respectively (Khan and La Thangue, 2012; Laubach et al., 2015).”
BackgroundPoised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301 · cited 1×
“Rewiring of signaling programs and epigenomic changes are increasingly being recognized as mechanisms of acquired drug resistance (Brown et al., 2014; Holohan et al., 2013; Sharma et al., 2010).”
BackgroundFiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N. (2014) · Leukemia · doi:10.1038/leu.2014.119 · Cited by 284 · cited 1×
“Moreover, pre-clinical studies have indicated that combination therapies involving HDAC inhibitors and some of the emerging epigenetic therapies may prove clinically beneficial (Fiskus et al., 2014; Mazur et al., 2015).”
BackgroundGibaja, V, Shen, F., Harari, J., Korn, J., Ruddy, D., Saenz-Vash, V, Zhai, H., Rejtar, T., Paris, C. G., Yu, Z., et al. (2016) · Oncogene · doi:10.1038/onc.2015.114 · Cited by 149 · cited 2×
“These mutations render the PRC2 complex insensitive to treatment with EZH2 inhibitors, potentially by reducing the ability of these compounds to bind EZH2 (Gibaja et al., 2015).”
BackgroundRexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Cited by
Metabolism of Amino Acids in Cancer
Wei, Z., Liu, X., Cheng, C., Yu, W., & Yi, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603837 · Cited by 429
Arechederra, M., Daian, F., Yim, A., Bazai, S. K., Richelme, S., Dono, R., Saurin, A. J., Habermann, B. H., & Maina, F. (2018) · Nature Communications · doi:10.1038/s41467-018-05550-5 · Cited by 221
Epigenetics of hematopoiesis and hematological malignancies
Hu, D., & Shilatifard, A. (2016) · Genes & Development · doi:10.1101/gad.284109.116 · Cited by 168
“Indeed, inhibitors targeting chromatin-modifying enzymes are being used in clinical trials (Cai et al. 2015; Brien et al. 2016).”
MethodEpigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
“Epigenetics refers to heritable traits not attributable to changes in DNA sequence that can control chromatin structure and the accessibility of the transcriptional machinery to DNA, thereby modulating gene expression.(32) These mechanisms are thus fundamental for the maintenance of cell identity, but are also heavily…”
Background
Metadata
- Authors
- Brien, G. L., Valerio, D. G., & Armstrong, S. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 29
- Issue
- 4
- Pages
- 464-476
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2322132473
- Cited by
- 145
- References
- 33
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.